Introduction
============

Campylobacteriosis is the main cause of foodborne diseases in the UE and in the United States \[[@B6]; (Accessed March 2018) ^[1](#fn01){ref-type="fn"}^\]. The drugs of choice for the treatment of campylobacteriosis were, mainly erythromycin (ERY) and ciprofloxacin (CIP), although quinolones are no longer effective after a fast rise in resistance mechanisms among *Campylobacter* species ([@B4]; [@B10]). Aminoglycosides, the third class of antimicrobials used worldwide after sulfonamides and beta-lactams, are a recommended alternative for the treatment of difficult infections caused by thermotolerant *Campylobacter* spp. ([@B32]). The advantages of using aminoglycosides compared to other antimicrobials are their concentration-dependent bactericidal activity and relatively predictable pharmacokinetics, and synergism with other antibiotics ([@B30]). Among aminoglycosides, the first active molecule used was streptomycin (STR), produced by *Streptomyces griseus*. STR binds to the aminoacyl-tRNA site (A site) of the 16S rRNA in the 30S ribosomal subunit, inducing codon misreading and inhibiting of translocation ([@B16]; [@B33]) which leads to inadequate protein production. When antibiotic resistance appears it is due to target modification of ribosomal components, antimicrobial modification, or lowering drug accumulation in the cell ([@B30]). Like in other bacteria, mutation K43R of S12 protein, a component of the 30S ribosomal subunit encoded by the *rpsL* gene, confers high-level of STR resistance in *Campylobacter* ([@B21]). Besides that, two out of four ANT(6)-I subfamily members of aminoglycoside nucleotidyltransferases (also known as aminoglycosides adenyltransferases of the AADE family), ANT(6)-Ia and ANT(6)-Ib, are frequently involved in STR resistance in *Campylobacter* strains and probably evolved from Gram-positive bacteria ([@B25]; [@B27]; [@B9]; [@B18]; [@B1]; [@B26]; [@B34]). An additional role in STR resistance of ANT-like protein has been suggested in *C. coli* ([@B20]).

The aim of this work was to characterize the STR resistance presented in *Campylobacter* isolates of human and animal origin, establishing the role of a new enzyme of the ANT(6)-I family, ANT(6)-Ie, detected in a significant fraction of STR resistant isolates which molecular typing evidenced spread between animal and human hosts.

Materials and Methods {#s1}
=====================

Bacteria and Antimicrobial Resistance
-------------------------------------

*Campylobacter* spp. strains isolated from humans were previously described ([@B10]) and resulted from systematical screenings performed during 2010--2012 in fecal samples from gastroenteritis patients by the Microbiology services of three hospitals located in West-Center Spain: San Pedro de Alcántara, Cáceres; Campo Arañuelo, Cáceres; and Universitario de Salamanca, Salamanca. *Campylobacter* spp. isolated from bovine, fattening pigs and poultry were randomly selected in 2010--2012 from slaughterhouses located all around Spain by the Spanish Surveillance Network of Antimicrobial Resistance in Bacteria of Veterinary Origin (VAV Network; [@B17]) and were partially described elsewhere ([@B8]). From each farm, a single *Campylobacter* isolate was obtained by culturing pooled feces from animals (bovine and porcine) and cloacal or meat samples (poultry). Isolates were grown on blood agar, in a microaerophilic atmosphere (CampyGenTM, Thermo Scientific) at 42°C for 24--48 h and were identified by a Vitek-MS MALDI-TOF system (bioMérieux, Marcy-l'Etoile, France) to species level. The minimal inhibitory concentrations (MICs) for STR, ERY, gentamicin (GEN), CIP, and tetracycline (TET) were determined by agar dilution methods according to the guidelines of CLSI ([@B5]), including *Campylobacter jejuni* ATCC 33560 as the reference strain. Resistance was determined according to the EUCAST ^[2](#fn02){ref-type="fn"}^ (last accessed September of 2018), by using cut-off values \[ecological cut-off value (ECOFF)\] of 4 mg/L for STR, 4 mg/L (*C. jejuni*) or 8 mg/L (*C. coli*) for ERY, 2 mg/L for GEN, 0.5 mg/L for CIP, and 1 mg/L (*C. jejuni*) or 2 mg/L (*C. coli*) for TET. To test the presence of efflux pumps, MIC to STR were determined in the presence of the efflux pump inhibitor phenylalanine-arginine beta-naphthylamide (PaβN, Sigma) at a concentration of 20 mg/L.

Detection of Resistance Determinants
------------------------------------

PCR was performed on DNA obtained by boiling, for 5 min, a suspension of one or two colonies from pure culture in 250 μL of milli-Q water, and recovering the supernatant after centrifugation at 10,000 ×*g* for 10 min. PCR was carried out with 1 μl of DNA, 0.2 mM of each dNTP (Biotools, Madrid, Spain), 0.5 μM of each primer \[Stab Service (University of Extremadura, Badajoz, Spain)\], 0.025 U/μl of Taq Polymerase (Biotools, Madrid, Spain) and 1X PCR buffer containing 1.5 mM MgCl~2~ (Biotools, Madrid, Spain), during 30 cycles of 94°C, 30 s; annealing temperature indicated in Table [1](#T1){ref-type="table"}, 30 s; 72°C, 1 min. Amplicon purification was done with Speedtools PCR clean-up kit (Biotools, Madrid, Spain), following the manufacturer's instructions. DNA sequencing were performed by STAB Service (DNA Sequencing facilities of the Universidad de Extremadura, Spain). *In silico* data analysis was carried out with bioinformatics tools available in NCBI^[3](#fn03){ref-type="fn"}^, SMS^[4](#fn04){ref-type="fn"}^, and EBI^[5](#fn05){ref-type="fn"}^.

###### 

Primers used in this work.

  Name     Sequence (5′-3′)                        T^1^   Bp^2^    Reference
  -------- --------------------------------------- ------ -------- -----------
  RPSLF    CCAGCGCTTAAAAAT TGTCC                   55     247      [@B21]
  RPSLR    TATCAAGAGCACCA CGAACG                                   
  INT1F    GGCTCTCGGGTAAC ATCAAGG                  54     242      [@B12]
  INT1R    TCAGGAGATCGGAA GACCTC                                   
  CSF      GGCATCCAAGCAGCAAG                       56     VAR^3^   [@B13]
  CSR      AAAAGCAGACTTGA CCTGA                                    
  SAF      TGCAAAA(G/A)CC(G/C) GA(A/G)GATATGG      56     305      This work
  SAR      TTCCTT(G/T)CG(G/A) CATA(G/T)CC(C/T)TT                   
  SBF      GATTGT(T/C)CG(T/C)CAT GAGCTGCT          57     327      This work
  SBR      GTGCTATCCAGGCAGC CGGTT                                  
  SCF      TGCCT(A/C)AAATTGG(G/A) T(G/A)AGTT       52     368      This work
  SCR      ACCTAGCCA(A/G)ATTTCA AA(A/G)CCAAA                       
  STREJF   TGCAAAGCGAAAA AAGAAT                    49     878      This work
  STREJR   TTATAATTTTCTTAAAAT TTTGCAAT                             
  STRECF   TGCAAAATCAAGATAAAT TTTTAAAAC            51     899      This work
  STRECR   TTACAATTTTCCTAAAAT TTTACAAT                             
  STREFF   GTATGCGCAAAAATGAT TAAAG                 50     1110     This work
  STREFR   AAGGAAAAATTTAAATAT TGGTTTCA                             
                                                                   

1

Annealing temperatures for PCR.

2

PCR-Product size in bp.

3

Variable size depending on gene-cassette structure (

Lévesque et al., 1995

).

Mutations in the STR resistance region of the *rpsL* gene were screened by sequencing of the PCR amplicon produced by primers and conditions previously described (Table [1](#T1){ref-type="table"}; [@B21]). Similarly, the possible presence of *ant(3")-Ia* genes carried by Class-I integrons was evaluated by PCR with primers specific to *intI* and *intI*-associated gene cassettes (Table [1](#T1){ref-type="table"}). Three sets of degenerated primers were designed to amplify internal fragments of genes *ant(6)-I* (Table [1](#T1){ref-type="table"}): *ant(6)-Ia* (primers SAF and SAR), *ant(6)-Ib* (primers SBF and SBR), and *ant(6)-Ie* (primers SEF and SER). Further analysis was performed to amplify the (almost) full coding sequences of *ant(6)-Ie* genes (Table [1](#T1){ref-type="table"}) from *C. jejuni* (primers STREJF and STREJR) and *C. coli* (primers STRECF and STRECR). Oligonucleotide design was performed with Oligo v.6 software.

Functional Expression in *E. coli*
----------------------------------

The expression of *ant(6)-Ie* from *C. coli* was tested through cloning the complete gene in the vector pGem-T Easy (Promega^®^), according to the manufacturer's instructions. The full length of the gene including its promoter sequence was amplified by using primers STREFF and STREFR (Table [1](#T1){ref-type="table"}), designed from the genome sequence of *C. coli* Z163 (ZP_14079546.1) and assuming that σ^70^ *Campylobacter* promoters have a well-conserved -10 box and lack the -35 box presented in other bacteria ([@B23]). The ligation mixture was electroporated in *Escherichia coli* XL1-Blue MRF' and transformants were selected in Luria-Bertani medium supplemented with 100 mg/L ampicillin.

Multilocus Sequence Typing of *Campylobacter* Isolates From Human and Animal Origin
-----------------------------------------------------------------------------------

A group of *Campylobacter* isolates was genotyped for *fla*A-SVR (short variable region of *fla*A gene) and multilocus sequence typing (MLST). PCR fragments of the housekeeping genes *asp*A (aspartase A), *gln*A (glutamine synthetase), *glt*A (citrate synthase), *gly*A (serine hydroxymethyltransferase), *pgm* (phosphoglucomutase), *tkt* (transketolase), and *unc*A (ATP synthase a subunit), as well as *fla*A gene (flagellin), were amplified and sequenced as described elsewhere ([@B29]). Allele numbers were assigned by sequence comparisons against the existing sequences deposited in the *Campylobacter* MLST database^[6](#fn06){ref-type="fn"}^.

Results
=======

Streptomycin Resistance Phenotypes in Isolates From Human Origin
----------------------------------------------------------------

Based on the ECOFF defined by EUCAST for STR resistance of *Campylobacter* (MIC \> 4 mg/L), 16 out of 141 human isolates are above the threshold (Figure [1](#F1){ref-type="fig"}). Among these it was possible to identify three different phenotypes: high-level resistance, shown by two *C. jejuni* strains (MIC \> 512 mg/L), medium-level resistance, in two *C. jejuni* and five *C. coli* isolates (32 ≤ MIC ≤ 256 mg/L), and low-level resistance, with inhibition of growth immediately above ECOFF, detected in six *C. jejuni* and one *C. coli* (MIC = 8 mg/L). Treatment with the efflux pump inhibitor PAβN reduced MICs in all the isolates, with the exception of the highly resistant HSA40, with maximal susceptibility attained in two isolates from the medium-level resistance group plus in the seven isolates with the lowest resistance level (Figure [1](#F1){ref-type="fig"}). Among analyzed isolates, low susceptibility against clinically relevant antimicrobials was generally found to CIP and/or TET but not to ERY or GEN, although three low-level resistant strains to STR were also found near the cut-off for CIP and TET (HCC26, HCC27, and HCC34; Figure [1](#F1){ref-type="fig"}).

![Phenotypic and genotypic analysis of streptomycin (STR) resistant isolates. ^1^Minimal inhibitory concentrations for STR, erythromycin (ERY), gentamicin (GEN), ciprofloxacin (CIP), and tetracycline (TET). ^2^MIC were determined in the presence of PaβN (mg/L). ^3^Data previously reported ([@B10]). ^4^Mutations in the RPSL coding sequence were detected by sequencing (WT, no mutation). ^5^Genes *ant(6)-I* were amplified with PCR with specific primers. ND, not determined.](fmicb-09-02515-g001){#F1}

*rpsL* Polymorphism Among Streptomycin Resistant Isolates
---------------------------------------------------------

The *rpsL* gene region determining resistance to aminoglycosides ([@B21]) was amplified and sequenced in 15 *Campylobacter* isolates with MICs above STR ECOFF value (Accession Nos. LT605180, LT605181, LT605182, LT605184, LT605185, LT605186, LT605187, LT605190, LT605191, LT605192, LT605193, LT605194, LT605195, LT605196, and LT605197). Among 11 polymorphic positions detected, only one was expressed at protein level corresponding to mutation K43R (not shown). This occurred in two *C. jejuni* isolates, HSA32 and HSA40 (Accession Nos. LT605194 and LT605195), having both the high-level resistant phenotype (Figure [1](#F1){ref-type="fig"}).

The ANT(6)-I Family in *Campylobacter*
--------------------------------------

The NCBI database includes sequences for three members of the ANT(6) protein family previously described in *Campylobacter*: ANT(6)-Ia, ANT(6)-Ib, and ANT-like sequence cluster ([@B1]; [@B20]). The phylogenetic relationships previously defined within the ANT(6)-I family ([@B1]) were re-analyzed (Figure [2](#F2){ref-type="fig"}), including *C. jejuni* and *C. coli* for clusters ANT(6)-Ia and ANT(6)-Ib, plus the new and distantly related family member previously identified as ANT-like ([@B20]). Supported by bootstrapping with a threshold near 70%, ANT-like sequences cluster is a new member of the protein family that will be named hereafter ANT(6)-Ie (Figure [2](#F2){ref-type="fig"}), the fifth described ANT(6) (aminoglycoside 6-adenyltransferase) enzyme.

![The ANT(6)-I phylogenetic tree. Multiple sequence alignment was performed by Clustal X 2.1. The phylogenetic tree was deduced by neighbor joining algorithm, excluding positions with gaps and emulated by NJPlot 2.3. Bootstrap values (N, 100; seeds, 111) are indicated for branches supporting sequence clustering and assuming previous data ([@B1]).](fmicb-09-02515-g002){#F2}

ANT(6)-I Detection in Streptomycin Resistant Isolates
-----------------------------------------------------

The role of ANT(6)-I enzymes on STR resistance of *Campylobacter* was addressed by using specific primers designed to detect the coding sequences for ANT(6)-Ia, ANT(6)-Ib, and ANT(6)-Ie, including degenerated positions for efficient amplification of homologs of either *C. jejuni* or *C. coli* for every subfamily (Table [1](#T1){ref-type="table"}). Among the 16 *Campylobacter* isolates resistant to STR detected in this work from human infections, nine were positive for the presence of *ant(6)-I* genes with two isolates positive for the subfamilies *ant(6)-Ia*, one for *ant(6)-Ib* and seven for *ant(6)-Ie* (Figure [1](#F1){ref-type="fig"}). The unique two *C. jejuni* isolates presenting *ant(6)-Ie* also have the RSPL polymorphism K43R and the high-resistance phenotype, whereas the six isolates with low-level of resistance did not carry any of the screened genes.

The nucleotide sequences of the seven *ant(6)-Ie* genes detected among human isolates, including the six *Campylobacter* strains presenting this gene as the unique aminoglycoside 6-adenyltransferase enzyme, revealed different functional roles on STR resistance depending on *Campylobacter* species. The *ant(6)-Ie* genes from the two *C. jejuni* isolates were found non-functional when compared with the reference used to define the protein subfamily (ZP_01070142, Figure [2](#F2){ref-type="fig"}), sharing both the unique polymorphism C-394-Δ (Accession No. LT605198, isolate HSA32), an out of frame deletion that produces the premature arrest of translation and the loss of 55% of protein sequence from its C-terminal end. In contrast, the four *ant(6)-Ie* genes from *C. coli* strains HCC2, HSA28, HSA86, and HCC46 presented identical sequences to ZP_14079546.1, whereas the polymorphism C466T originating variant P156S in the encoded protein was detected in the gene from HNA4 isolate (Accession No. LT605200).

Functional Expression in *E. coli* of ANT(6)-Ie
-----------------------------------------------

The coding sequence for ANT(6)-Ie from HNA4 was amplified and cloned in pGEM-T vector and *E. coli* XL1 Blue (MRF') cells. Cells carrying the recombinant vector expressed resistance to STR with a MIC of 64 mg/L, significantly higher than the control cells transformed with a non-recombinant vector (MIC = 8 mg/L). Besides, both recipient and transformants cells remained sensitive to other antimicrobials tested showing aminoglycoside specificity of the *ant(6)-Ie* gene: spectinomycin (MIC ≤ 32 mg/L), GEN (MIC ≤ 1 mg/L), apramycin (MIC ≤ 4 mg/L), and neomycin (MIC ≤ 4 mg/L).

Genetic and Phenotype Relationships Among Human and Animal Streptomycin Resistant Isolates Carrying ANT(6)-Ie
-------------------------------------------------------------------------------------------------------------

We screened for the three ANT(6)-I encoding genes in *Campylobacter* among 65 STR resistant isolates from the three most common food-producing livestock: poultry, pigs, and cattle (Table [2](#T2){ref-type="table"}). All *ant(6)-I* genotypes were detected, with *C. coli* being largely the most prevalent species among streptomycin resistant isolates. Interestingly, the presence of the single-gene *ant(6)-Ie* genotype represents a major fraction of STR resistant *C. coli*, with one fourth of isolates.

###### 

*ant(6)-I* genotypes of streptomycin resistant *Campylobacter* isolates.

  Host       *ant(6)-I* profile^1^                                                        
  ---------- ----------------------- ------ -------- -------- ------ ------ ------ ------ ---------
  Human^2^   1                       1      6(4)     \-       \-     1(1)   \-     7(1)   16 (6)
  Poultry    13(8)                   1(1)   \-       10(9)    1(1)   \-     2(1)   5(1)   32 (21)
  Porcine    4(4)                    \-     10(10)   2(2)     7(7)   4(4)   1(1)   1(1)   29 (29)
  Bovine     2(1)                    \-     1(1)     \-       1(1)   \-     \-     \-     4 (3)
  Σ          20(13)                  2(1)   17(15)   12(11)   9(9)   5(5)   3(2)   6(3)   81 (59)
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1

. Data in parentheses refer to number of isolates belonging to
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species. Ø, zero genes detected.

Multilocus sequence typing plus *flaA* typing was performed in 14 *C. coli* isolates carrying *ant(6)-Ie* as the only determinant expressing STR resistance (Table [3](#T3){ref-type="table"}). The multilocus analysis allowed the detection of a cluster of strains (ST-827, clonal complex 828) including two isolates from human origin plus one from bovine. Moreover, one of the human and the bovine origin isolates shared the same *flaA* allele 236 and the same resistance profile against the five clinically relevant antimicrobials tested, which is considered an indication of a probable common clonal origin.

###### 

Molecular and antimicrobial resistance typing of *Campylobacter* isolates carrying^1^ *ant(6)-Ie*.

                                    MIC (mg/L)^2^                                          
  ---------------- ------ --------- --------------- ----- --- ------ ----- -------- ------ ------
  ZTA10/00526CPD   2010   Porcine   ≥32             1     4   ≥8     ≥32   ST-828   7337   ND
  ZTA10/00602CPD   2010   Porcine   ≥32             ≥64   4   ≥8     ≥32   ND       7340   ND
  ZTA10/00794CPD   2010   Porcine   ≥32             1     4   ≥8     ≥32   ST-828   829    ND
  ZTA10/01257CPD   2010   Bovine    ≥32             1     2   ≥8     ≥32   ST-828   827    0236
  ZTA10/01418CPD   2010   Porcine   ≥32             ≥64   2   ≥8     ≥32   ST-828   1413   ND
  ZTA10/02049CPD   2010   Porcine   ≥32             2     2   ≥8     ≥32   ST-828   4950   ND
  ZTA11/00514CP    2011   Porcine   ≥32             ≥64   2   ≥8     ≥32   ND       7341   0662
  ZTA11/00726CP    2011   Porcine   ≥32             1     4   0.13   ≥32   ST-828   7338   ND
  ZTA11/01342CP    2011   Porcine   ≥32             ≥64   4   0.25   ≥32   ST-828   1413   ND
  ZTA11/03282CP    2011   Porcine   ≥32             0.5   1   ≥8     ≥32   ST-828   1096   0319
  ZTA11/03389CP    2011   Porcine   ≥32             ≥64   2   ≥8     ≥32   ST-828   2733   ND
  HSA028           2010   Human     128             8     2   32     256   ST-828   827    0236
  HSA046           2010   Human     64              2     2   0.25   256   ST-828   827    0255
  HNA4             2010   Human     32              2     2   2      256   ND       7339   0633
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alleles were assigned by MLST database (see footnote 6). ND, not determined.

Discussion
==========

This work shows the main role of adenylyl transferases belonging to the ANT(6)-I family on STR resistance in *Campylobacter*. Previous reports had described the phenotypic expression of ANT(6)-I enzymes ([@B18]; [@B1]; [@B26]; [@B20]), and now strong evidence is provided supporting the role of ANT(6)-Ie on STR resistance. Although ANT(6)-Ie coding sequences were detected in the two most frequent *Campylobacter* species, *C. jejuni* and *C. coli*, the association with STR resistance was only proved in *C. coli* since no *C. jejuni* isolate carried this coding sequence as the unique candidate to express the phenotype (Figure [1](#F1){ref-type="fig"} and Table [2](#T2){ref-type="table"}).

Besides ANT(6)-I, an additional STR resistance determinant is ANT(3")-Ia or AADA which also confers resistance to spectinomycin. This enzyme is highly prevalent among enterobacteria ([@B27]) and has been detected associated to class I integrons and their gene cassettes in *Campylobacter*, although only anecdotally ([@B22]; [@B19]). Indeed, several reports have described the unsuccessful search of *ant(3")* in *Campylobacter* ([@B31]; [@B24]). Similarly, all STR resistant isolates from humans analyzed in the present work have been screened for *int1* or associated gene cassettes, unsuccessfully (data not shown). Thus, ANT(6)-I enzymes might be the unique adenylyl transferases with significant relevance in STR resistance in *Campylobacter*.

To the best of our knowledge, this is the first report showing a RPSL mutation in *C. jejuni* isolates conferring STR resistance. In a previous study, with *C. coli*, it was found that isolates presenting high-level resistance to STR shared the mutation K43R in RPSL ([@B21]), similarly to the two *C. jejuni* isolates from humans, detected in this work, with MIC \> 512 mg/L (Figure [1](#F1){ref-type="fig"}). Although both isolates also carry *ant(6)-Ie* genes, resistance to STR might be determined by RPSL mutation since the adenylyl transferase coding sequence is truncated and most probably not functional. In addition, there was no contribution to this phenotype from efflux pump activity, as deduced by the lack of any effect on MIC by PAβN treatment (Figure [1](#F1){ref-type="fig"}).

A group of six *C. jejuni* and one *C. coli* isolates from humans that expressed low-level STR-resistance, did not contain any of the screened determinants and presented a strong decreased MIC to STR in the presence of PAβN (Figure [1](#F1){ref-type="fig"}). Thus, efflux pump activity must be responsible for low-level STR resistance of these strains, similarly to *Mycobacterium tuberculosis* where the effect of outward transporters is known to increase modestly the MIC for STR ([@B28]). At least three different efflux pump systems have been shown to be up-regulated in *Campylobacter* strains resistant to a broad range of antimicrobials ([@B14]; [@B2]; [@B11]), so they could be candidates for determinants to the low level STR resistance. In addition, treatment with PAβN produced a strong effect on MIC of *Campylobacter* isolates carrying *ant(6)-I* genes, mostly for those with *ant(6)-Ia* or *ant(6)-Ib* as unique resistance determinants (Figure [1](#F1){ref-type="fig"}). This observation might indicate that, among human isolates analyzed in this work, the only functional adenylyl transferase gene is *ant(6)-Ie* and that even these isolates require efflux pump activity to support the medium-level of resistance. Treatment of *ant(6)-Ie* carrying strains with PAβN reduces their STR MIC to low-level resistance, which might correspond to their *in vivo* expression level. Synergic effects of efflux pumps have been evidenced in *Campylobacter* with resistance determinants for quinolones and macrolides, *gyr*A and 23S rRNA gene mutations, respectively ([@B15]; [@B3]; [@B7]). Indeed, three *Campylobacter* isolates showing low-level resistance to STR were also found to have low-level resistant to CIP and TET (Figure [1](#F1){ref-type="fig"}), lacked the *gyrA* C-257-T mutation conferring low susceptibility to fluoroquinolones ([@B10]) and also *tetO*, the major TET resistant determinant in this species (not shown, authors' personal communication). A weak overexpression of efflux pump activity might be involved in the antimicrobial resistance phenotype of these strains.

The set of primers described in this work allows specific detection of the three *ant(6)-I* genes described in *Campylobacter*, including those belonging to *ant(6)-Ie* and encoding a new subfamily of aminoglycoside O-nucleotidyltransferases (Figure [2](#F2){ref-type="fig"}) that provides functional information for hundreds of orthologs annotated as hypothetical proteins, mainly from *Campylobacter* and related organisms like *Helicobacter*. In addition, the molecular and antimicrobial resistance typing of *Campylobacter* isolates expressing ANT(6)-Ie has revealed a spread pathway for this zoonotic pathogen between cattle and humans.
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